Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site

Lyon, France, 1 April 2019 – Following a pre-signed agreement in October 2018, Boehringer Ingelheim and Dopharma are announcing today the effective acquisition of the Saint-Herblon (France, Loire-Atlantique) production site and the Coophavet brand by Dopharma. This independent and family-owned Dutch company develops, produces and distributes veterinary products 100 per cent dedicated to livestock.

This sale is part of Boehringer Ingelheim Animal Health’s strategic refocusing on advanced and preventive animal healthcare; Saint-Herblon mainly producing generics and antibiotics for livestock, under the Coophavet brand.

For Dopharma, a growing player on the market, already distributing in more than 50 countries, this acquisition represents a significant asset in addition to its European-based production sites.

Boehringer Ingelheim had taken the effort to identify a strong buyer in order to offer a sustainable future for the site and its employees. By establishing its presence in France, and thanks to its complementary portfolio, Dopharma’s ambition is indeed to develop the site and Coophavet’s activity as well as its international presence. Moreover, Boehringer Ingelheim and Dopharma will continue to collaborate in the coming years to manufacture some specialised products.

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of 3.9 billion euros (2017) and around 10,000 employees worldwide, we are present in more than 150 markets. For more information visit: https://www.boehringer-ingelheim.com/animal-health/overview.

Dopharma

Dopharma is a family owned veterinary pharmaceutical company with its headquarters in the Netherlands. Dopharma delivers high quality veterinary pharmaceuticals for livestock since its establishment in 1969. Started as a one-man business and grown into a company with 6 production lines and 165 employees. Dopharma’s products are sold in over 50 countries by 4 local subsidiaries and approximately 40 distribution partners. Dopharma produces antibacterial, antiparasitic and anti-inflammatory products as well as hormone preparations, corrective preparations and complementary feed. In 2017 Dopharma has acquired a majority share in RIPAC-Labor specialised in the development and production of autogenous vaccines. Together we work towards clever and sophisticated solutions in order to achieve the best results possible.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.